Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. Κυριότερες Ειδήσεις

   • Becker's Hospital Review

     FDA adds warning to Ozempic, Mounjaro and other GLP-1 labels

     The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration during general anesthesia or deep sedation, Medscape reported Nov. 6.

     2 ώρες Πριν από

   • 

     Vietnam Investment Reviev

     FDA accepts new drug application and grants priority review for TLX101-CDx brain cancer imaging agent

     2 εβδομάδες Πριν από

   • 

     Cryptopolitan on MSN.com

     FDA’s new device chief faces growing pressure as AI and tech transform healthcare

     4 ημέρες Πριν από

   • Taiwan News

     FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

     [2] Prescription User Drug Fee Act. [3] Subject to FDA marketing authorsation approval. [4] Joint European Association of Nuclear Medicine//European Association of Neurooncology/Response Assessment in Neurooncology practice guidelines/Society for Nuclear ...

     2 εβδομάδες Πριν από

   • Targeted Oncology

     FDA Grants Priority Review for TLX101-CDx PET Imaging Agent in Glioma

     2 εβδομάδες Πριν από

2. www.fda.gov › drugs › guidances-drugsNewly Added Guidance Documents | FDA - U.S. Food and Drug...

   www.fda.gov › drugs › guidances-drugs

   • Αποθηκευμένο αντίγραφο

   25 Οκτ 2023 · Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.

   • Interstitial Cystitis/Bladder Pain Syndrome

     Dockets Management Food and Drug Administration 5630 Fishers...

   • Nonclinical Information

     FDA has received an increasing number of questions regarding...

3. www.fda.gov › drugs › news-events-human-drugsWhat's New Related to Drugs | FDA

   www.fda.gov › drugs › news-events-human-drugs

   • Αποθηκευμένο αντίγραφο

   26 Ιουλ 2024 · Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

4. www.fda.gov › drugs › drug-safety-and-availabilityFDA clarifies policies for compounders as national GLP-1 supply...

   www.fda.gov › drugs › drug-safety-and-availability

   • Αποθηκευμένο αντίγραφο

   The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in ...

5. www.nature.com › articles › d41573/024/00001-x2023 FDA approvals - Nature

   www.nature.com › articles › d41573/024/00001-x

   • Αποθηκευμένο αντίγραφο

   2 Ιαν 2024 · A nine-person FDA advisory panel voted unanimously that the data supports a “reasonably likely” chance that the drug helps people, based on the constellation of evidence.

6. www.boehringer-ingelheim.com › us › mediaFDA Accepts Application for Jardiance® (empagliflozin) Review |...

   www.boehringer-ingelheim.com › us › media

   • Αποθηκευμένο αντίγραφο

   RIDGEFIELD, Conn. and INDIANAPOLIS, November 11, 2021 – The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance® (empagliflozin) 10 mg, which is being investigated as a potential new treatment to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure ...

7. www.reuters.com › us-fda-advisers-review-eli-lilly-alzheimers-drug-2024/06/10Lilly Alzheimer's drug gets unanimous backing from FDA advisory...

   www.reuters.com › us-fda-advisers-review-eli-lilly-alzheimers-drug-2024/06/10

   10 Ιουν 2024 · June 10 (Reuters) - Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly's (LLY.N) experimental Alzheimer's treatment donanemab...

8. www.medcentral.com › drug-newsFDA Actions & Drug News | MedCentral

   www.medcentral.com › drug-news

   • Αποθηκευμένο αντίγραφο

   Kelsey Giara, PharmD, RPh. The U.S. FDA has approved ZUNVEYL (benzgalantamine) which aims to reduce GI-related side effects compared to existing medications for Alzheimer’s disease. Stay informed with the latest FDA approvals, actions, and drug news. Timely updates for healthcare professionals to enhance patient care.